Is antimicrobial stewardship cost-effective? A narrative review of the evidence

Clinical Microbiology and Infection

Volumn 23, Issue 11, 2017, Pages 806-811

  Naylor, N R ^a   Zhu, N ^a   Hulscher, M ^b   Holmes, A ^a   Ahmad, R ^a   Robotham, J V ^a,c  

^a The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antimicrobial resistance; Antimicrobial stewardship; Cost effectiveness; Cost benefit; Review

Indexed keywords

ANTIINFECTIVE AGENT;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; REVIEW; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; ECONOMICS; STATISTICS AND NUMERICAL DATA;

ANTIMICROBIAL STEWARDSHIP; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 85027158433     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.06.011     Document Type: Review

References (32)

1. O'Neill, J., Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014.
2. Stewardson, A.J., Allignol, A., Beyersmann, J., Graves, N., Schumacher, M., Meyer, R., et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Eurosurveillance 21 (2016), 1–12.
3. Doron, S., Davidson, L.E., Antimicrobial stewardship. Mayo Clinic Proc 86 (2011), 1113–1123.
4. Dyar, O., Huttner, B., Schouten, J., Pulcini, C., What is antimicrobial stewardship?. Clin Microbiol Infect 23:11 (2017), 793–798.
5. Davey, P., Marwick, C., Scott, C., Charani, E., McNeil, K., Brown, E., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients (Review) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev(2), 2017, CD003543.
6. Van Den Hout, W.B., Caljouw, M.A.A., Putter, H., Cools, H.J.M., Gussekloo, J., Cost-effectiveness of cranberry capsules to prevent urinary tract infection in long-term care facilities: economic evaluation with a randomized controlled trial. J Am Geriatrics Soc 62 (2014), 111–116.
7. National Institute for Health and Clinical Excellence (NICE), Guide to the methods of technology appraisal 2013. 2013, NICE, London.
8. Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., et al. Methods for the estimation of the National Institute for Health and care excellence cost-effectiveness threshold. Health Technol Assess 19:14 (2015), 1–503.
9. Ackerman, F., Heinzerling, L., Pricing the priceless: cost–benefit analysis of environmental protection. Univ Penn Law Rev, 150, 2002, 1553.
10. Dik, J.H., Vemer, P., Friedrich, A.W., Hendrix, R., Lo-ten-foe, J.R., Sinha, B., et al. Financial evaluations of antibiotic stewardship programs — a systematic review. Front Microbiol, 6, 2015, 317.
11. Coulter, S., Merollini, K., Roberts, J.A., Graves, N., Halton, K., The need for cost-effectiveness analyses of antimicrobial stewardship programmes: a structured review. Int J Antimicrob Agents 46 (2015), 140–149.
12. Hulscher, M., Prins, J., Antibiotic stewardship: does it work in hospital practice? A review of the evidence base. Clin Microbiol Infect 23:11 (2017), 799–805.
13. Department of Health, Department for Environment Food and Rural Affairs, UK five year antimicrobial resistance strategy 2013 to 2018. 2013, DEFRA, London.
14. Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W., Methods for the economic evaluation of health care programmes, vol. 3, 2005, Oxford University Press, Oxford, 379.
15. Okumura, L.M., Riveros, B.S., Gomes-da-Silva, M.M., Veroneze, I., A cost-effectiveness analysis of two different antimicrobial stewardship programs. Braz J Infect Dis 20 (2016), 255–261.
16. Scheetz, M.H., Bolon, M.K., Postelnick, M., Noskin, G.A., Lee, T.A., Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. J Antimicrob Chemother 63 (2009), 816–825.
17. Brown, J., Paladino, J.A., Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model. Pharmacoeconomics 28 (2010), 567–575.
18. Heil, E., Daniels, L.M., Long, D.M., Rodino, K.G., Weber, D.J., Miller, M.B., Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections. Am J Health Syst Pharm 69 (2012), 1910–1914.
19. Slayton, R.B., Scott, R.D., Baggs, J., Lessa, F.C., Mcdonald, L.C., Jernigan, J.A., The cost–benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program. Infect Control Hosop Epidemiol 36 (2015), 681–687.
20. Borde, J.P., Nussbaum, S., Hauser, S., Hehn, P., Hübner, J., Sitaru, G., et al. Implementing an intensified antibiotic stewardship programme targeting daptomycin use in orthopaedic surgery: a cost–benefit analysis from the hospital perspective. Infection 44 (2016), 301–307.
21. Buyle, F.M., Metz-Gercek, S., Mechtler, R., Kern, W.V., Robays, H., Vogelaers, D., et al. Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals. Eur J Clin Microbiol Infect Dis 32 (2013), 1161–1170.
22. Mcgregor, J.C., Furuno, J.P., Optimizing research methods used for the evaluation of antimicrobial stewardship programs. Clin Infect Dis 59:Suppl. 3 (2014), 185–192.
23. Dik, J.H., Hendrix, R., Poelman, R., Niesters, H.G., Postma, M.J., Sinha, B., et al. Expert review of anti-infective therapy measuring the impact of antimicrobial stewardship programs. Exp Rev Anti-infect Ther 14 (2016), 569–575.
24. de Kraker, M., Abbas, M., Huttner, B., Harbarth, S., Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions. Clin Microbiol Infect 23:11 (2017), 819–825.
25. Wolowacz, S.E., Briggs, A., Belozeroff, V., Clarke, P., Doward, L., Goeree, R., et al. ISPOR task force report estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health 19 (2016), 704–719.
26. Husereau, D., Drummond, M., Petrou, S., Carswell, M., Moher, D., Greenberg, D., et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 16 (2013), 231–250.
27. Wilton, P., Smith, R., Coast, J., Millar, M., Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 7 (2002), 111–117.
28. Brock, D.W., Ethical issues in the construction of cost-effectiveness analyses for the prioritization and rationing of healthcare. The Proceedings of the Twentieth World Congress of Philosophy, vol. 1, 1999, 215–229.
29. De Angelis, G., D'Inzeo, T., Fiori, B., Spanu, T., Sganga, G., Burden of antibiotic resistant Gram negative bacterial infections: evidence and limits. J Med Microbiol Diagn 3 (2014), 1–6.
30. Gandra, S., Barter, D.M., Laxminarayan, R., Economic burden of antibiotic resistance: how much do we really know?. Clin Microbiol Infect 20 (2014), 973–980.
31. Smith, R., Coast, J., The true cost of antimicrobial resistance. BMJ (Clin Res Ed), 346(1), 2013, f1493.
32. NICE Medicines and Prescribing Centre, Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. 2015, NICE, London.